Risk factor
Very poor trading liquidity
Profitability factor
Undervalued vs peers
About
Whan In Pharm Co.,Ltd. is a South Korean pharmaceutical enterprise specializing in the research, development, manufacturing, promotion, and distribution of therapeutic products. Their comprehensive portfolio encompasses treatments for mental health conditions (such as antidepressants and antipsychotics), neurological disorders (including nootropics, anti-dementia, and anti-epileptics), cardiovascular and gastrointestinal ailments, infectious diseases, allergies, pain and inflammation, metabolic imbalances, respiratory issues, and a variety of other central nervous system applications. Established in 1978, the company's corporate headquarters are situated in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, over
Target Price
The average target price of 016580.KS is 17000 and suggests 71.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation t